F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. - Wikidata - awgldk - TriplyDB

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

http://www.wikidata.org/entity/Q37348247

about

¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review Imaging of multiple myeloma: Current concepts Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement New criteria for response assessment: role of minimal residual disease in multiple myeloma Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Advances in understanding prognosis in myeloma.(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma.Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy.Advances in the understanding of myeloma bone disease and tumour growth.Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation.Curing myeloma at last: defining criteria and providing the evidence.Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology.Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.Targeting bone as a therapy for myeloma.11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis.Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.Current and future imaging modalities for multiple myeloma and its precursor states.Myeloma today: Disease definitions and treatment advances.11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement Multiple Myeloma: Treatment is Getting Individualized Whole body diffusion weighted MRI--a new view of myeloma.Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3 Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin The molecular characterization and clinical management of multiple myeloma in the post-genome era.Pursuing the curative blueprint for early myeloma.Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?Multimodality imaging of osseous involvement In haematological malignancies Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response

P2860

Q26823362-9CFA86BF-1AFF-4C0B-BF6F-F85D667789FA Q26864616-BA1D9008-8B28-44BE-B3CB-9695AA0D2E7C Q27009240-E185E028-426F-4765-B468-A1CF29A5775D Q27011865-4EC8248C-5199-4AC8-87D1-419AE9D26D2D Q27027512-D88ED385-4F7E-44C7-9F4B-770B7D917C6E Q28082335-12398F2F-8318-4253-B4C7-35F6C4CCF7F9 Q30244061-15E10E52-C01E-4F90-A3CC-4CB9ED3DCE01 Q30561836-10EF5923-6089-4300-A57D-D6EB5D34A2AB Q33400076-15EE6344-570A-406F-92F8-F6D1CCB250F9 Q33401759-36C04B5A-7BA5-438B-BD5A-3A641356B41D Q33783925-34D6467D-7587-4B88-84C9-E0234395E567 Q33790254-E81202E6-5979-4261-93DE-7C9DA7CA2DBE Q33829022-BBE947C3-D003-4459-A86B-9E411206B784 Q34307388-D34E8987-C12F-45D5-B159-23922AECC550 Q34316959-F35F5A77-6977-4DF7-B762-4B1892AB8DE7 Q34365686-2954CBF8-F258-4C1E-AB0A-4EC6B889D8C1 Q34508313-A0B820D8-B2F5-45EF-879B-644BF9B47EC3 Q35078496-C73A97A5-FD1F-47B7-9E44-71CF4925F439 Q35219019-93B111EE-D47D-4EED-B97D-81E5411402A9 Q35595838-3CF66415-41DB-4D15-BBBD-BA0C18B334D4 Q35603128-ED93FB38-75FE-40CA-B464-818011200F6B Q35781619-2B69AF50-6062-468E-9DA2-4569D6E4BDB0 Q36010195-55D7C2DE-9631-408B-B45C-384B59D28370 Q36092153-AF166A68-509F-4331-81D3-C226ADF1A67E Q36123252-A7CB3068-B6EE-40DC-9076-F4F2CE719FFA Q36205152-FE7948FB-C3D7-475C-A612-9D0B8B05114C Q36205157-0408744A-51C1-4973-9F94-8BD9F774850E Q36288116-598F5BE9-8B92-4C35-8B75-26EEDE2FF7E7 Q36457735-FCAC353E-BF24-4FA6-8E94-B62BD415D202 Q36470699-A23E6583-8F42-4BC1-B020-003652C9D784 Q36510870-C30B7776-C1A9-4BC7-BA95-F38B9FC3CAE7 Q36522964-E20DCD6B-9522-45BC-88C4-8093CB017E9B Q36532924-7E0CB26D-9182-48EC-BF4B-775FAA64A3BB Q36666793-D83F0CA3-497C-4FB2-8597-0AD27697F2B2 Q36905125-7A2527ED-2279-4474-97AE-D4E5F000922A Q36939043-308060FC-39BD-45FF-A352-6776B38D12DE Q37046979-7C708A8F-1323-4CCE-AE25-E3890E739E2C Q37096649-7259B6EA-CBA4-4A07-9652-EBF14D5BEEF7 Q37178919-5F61EBDD-6644-40A0-89A4-8BC68E2A2DC8 Q37593761-38BB38EE-DD9C-4BBF-8781-BFB19D6D6563

P2860

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

http://www.wikidata.org/entity/Q37348247

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@en

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@nl

type

label

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@en

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@nl

prefLabel

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@en

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@nl

P1433

Q37348247-4C72BC82-02F7-43AA-8E9F-3A26B31FF982

P1476

Q37348247-2ED2D5D7-9B28-4D38-875F-CEE417B128D2

P2093

Q37348247-3BA1BC48-F9E2-4227-A645-75840415C121

Q37348247-53CBF498-5B00-465D-8E78-D1F7630B1F13

Q37348247-B3FB158D-B480-46BD-9FF7-27D80375C93E

Q37348247-B56C467B-4F3E-4119-B6CF-BD9B20A01509

Q37348247-B7B95B1B-3524-4FDD-914A-FD9EF2E32A93

Q37348247-D165467A-5128-4CA5-B9A9-58C2C8139463

Q37348247-DCF24979-F978-466F-A250-2652739BA9D0

Q37348247-E267B891-DDBB-4CCD-B105-0072023BD50A

Q37348247-EDAD3833-2A73-4CB5-B364-2F5A82892ADC

P2860

Q37348247-072D5F20-0147-4E6D-855D-36178396DA82

Q37348247-1136EE61-6FA9-4240-8189-64026A38A52F

Q37348247-190A3639-2601-4563-B346-79070C539540

Q37348247-257198FE-98C0-47AA-B0DC-B51FC414073A

Q37348247-28F68A6A-CDA1-4FCB-BC1E-3890BCE57397

Q37348247-30543176-1D08-4558-B5B5-D6890A168801

Q37348247-30B25F6D-10E4-4F8B-B7D1-E99C2CED6ED0

Q37348247-3B3944F4-874F-4B84-8E78-D12A00A3E219

Q37348247-42EB165F-9BFA-4BE7-822A-7502670EC8EC

Q37348247-4DF85361-247D-4675-B971-A4CB5C7FA51A

P304

Q37348247-D3BC1A7C-F5CE-4097-921A-AE2369DA46EE

P31

Q37348247-99B9CF3D-9F7E-45CF-8DF6-29669E690356

P356

Q37348247-9CF19762-9524-44AF-BEDF-8B7B9D42F862

P407

Q37348247-8677FB6A-2910-4736-837A-E30100F1453A

P433

Q37348247-C4C21F1C-9144-4DD1-9FFE-C86F6B2F51C2

P478

Q37348247-1EF39D9C-65AC-4917-8EEC-125B4412676F

P50

Q37348247-1A0BD9BF-0041-4748-B2F6-CC3C99C0641F

Q37348247-26830968-3C40-4858-9606-331774CB7BFB

Q37348247-99B49847-7410-445C-953E-976D8DCE19C8

P577

Q37348247-B4BF3622-430C-47F6-A2B3-F21A916857A2

P5875

Q37348247-43E6E93E-832E-42D3-89A8-2AAAD9673174

P698

Q37348247-9E2DB211-318B-4C35-9A73-4BDEAC6B41A0

P932

Q37348247-EA85B11C-8499-48C9-B40C-4C16D2164A81

P356

BLOOD-2009-03-213280

P1433

P1476

F18-fluorodeoxyglucose positro ...... c factors in multiple myeloma.

@en

P2093

Edgardo Angtuaco

http://www.w3.org/2001/XMLSchema#string

Jeff Haessler

http://www.w3.org/2001/XMLSchema#string

John Crowley

http://www.w3.org/2001/XMLSchema#string

John D Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Joshua Epstein

http://www.w3.org/2001/XMLSchema#string

Ronald Walker

http://www.w3.org/2001/XMLSchema#string

Terri Alpe

http://www.w3.org/2001/XMLSchema#string

Tracy L Y Brown

http://www.w3.org/2001/XMLSchema#string

Twyla B Bartel

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Mechanisms of bone metastasis.

Evaluation of survival data and two new rank order statistics arising in its consideration.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Imaging of myeloma bone disease--implications for staging, prognosis and follow-up.

Magnetic resonance and computed tomography imaging in multiple myeloma.

P304

2068-2076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-03-213280

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24428722

http://www.w3.org/2001/XMLSchema#string

P698

19443657

http://www.w3.org/2001/XMLSchema#string

P932

2744568

http://www.w3.org/2001/XMLSchema#string